MedTrace Logo

Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal Encephalopathy

NCT00896831 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2009-06-10

No results posted yet for this study

Summary

The study aimed to assess the effectiveness and safety of L-ornithine-L-aspartate in the management of hepatic encephalopathy.

Conditions

  • Hepatic Encephalopathy

Interventions

DRUG

L-ornithine-L-aspartate

L-ornithine-L-aspartate: 5 g (1 sachet) three times per day for 60 days

DRUG

placebo

Placebo: 5 g (1 sachet) three times per day for 60 days

Sponsors & Collaborators

  • Hospital de Clinicas de Porto Alegre

    lead OTHER

Principal Investigators

  • Mário R Álvares-da-Silva, PhD · Hospital de Clínicas de Porto Alegre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2010-03-31
Completion
2010-09-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00896831 on ClinicalTrials.gov